Document ID: chunk:federal_register_of_legislation:F2022C00575:front:0:p3
Version: federal_register_of_legislation:F2022C00575
Segment Type: other
Provision Reference: 
Character Range: 6106–9205

the clinical onset of acute lymphoblastic leukaemia/lymphoblastic lymphoma;
            Note: cumulative equivalent dose is defined in the Schedule 1 - Dictionary.
(2)          taking an alkylating agent or a DNA topoisomerase II inhibitor for the treatment of a malignant neoplasm before the clinical onset of acute lymphoblastic leukaemia/lymphoblastic lymphoma, and:
(a)          the first exposure occurred at least one year before the clinical onset of acute lymphoblastic leukaemia/lymphoblastic lymphoma; and
(b)          if exposure ceased before the clinical onset of acute lymphoblastic leukaemia/lymphoblastic lymphoma, then that onset occurred within 20 years of cessation;
(3)          undergoing organ or tissue transplantation, excluding corneal transplant, before the clinical onset of acute lymphoblastic leukaemia/lymphoblastic lymphoma;
            Note: organ or tissue transplantation is defined in the Schedule 1 - Dictionary.
(4)          being exposed to benzene as specified:
(a)          for a cumulative total of at least 2,500 hours within a continuous period of five years before the clinical onset of acute lymphoblastic leukaemia/lymphoblastic lymphoma; and
(b)          where the first exposure in that period occurred at least five years before the clinical onset of acute lymphoblastic leukaemia/lymphoblastic lymphoma;
            Note: being exposed to benzene as specified is defined in the Schedule 1 - Dictionary.
(5)          being exposed to benzene:
(a)          in an amount greater than ten ppm-years of cumulative exposure before the clinical onset of acute lymphoblastic leukaemia/lymphoblastic lymphoma; and
(b)          where the first exposure occurred at least five years before the clinical onset of acute lymphoblastic leukaemia/lymphoblastic lymphoma;
             Note: ppm-years is defined in the Schedule 1 - Dictionary.
(6)          inability to obtain appropriate clinical management for acute lymphoblastic leukaemia/lymphoblastic lymphoma.
     10           Relationship to service
(1)          The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.
(2)          The factor set out in subsection 9(6) applies only to material contribution to, or aggravation of, acute lymphoblastic leukaemia/lymphoblastic lymphoma where the person's acute lymphoblastic leukaemia/lymphoblastic lymphoma was suffered or contracted before or during (but did not arise out of) the person's relevant service.
     11           Factors referring to an injury or disease covered by another Statement of Principles
In this Statement of Principles:
(1)          if a factor referred to in section 9 applies in relation to a person; and
(2)          that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(2) of the VEA;
then the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.

Schedule 1 - Dictionary
Note: See Section 6